Compare ADMA Biologics Inc (ADMA) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Hyatt Hotels Corporation — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Hyatt Hotels Corporation trades at $187.9 (market cap $18.19B). The key difference: Hyatt Hotels Corporation is far larger — about 8.5× ADMA Biologics Inc's market cap, and Hyatt Hotels Corporation pays a 0.31% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | H | |
|---|---|---|
Market Cap | $2.13B | $18.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $202.09 |
52-Week Low | $7.60 | $135.01 |
Enterprise Value | $2.20B | $22.03B |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Hyatt Hotels (H) trades at $193.16, up 0.98% with a neutral technical signal. The stock shows mixed fundamentals with negative net income margins (-0.48%) and ROE (-1.02%) despite revenue growth to $7.1B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, while analyst consensus targets $197.30. The company continues expansion with new hotel announcements and maintains strong institutional support.
Investment outlook is cautiously optimistic given analyst buy ratings (37.5%) and expansion initiatives, but risks include declining cash flow trends and elevated debt levels. The stock faces pressure from negative profitability metrics despite revenue stability, requiring careful monitoring of upcoming Q2 2026 earnings against the $0.89 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
